Jurnal - INF - Successful Treatment of Phlyctenular Keratoconjunctivitis With Topical - HV - 2018

Download as pdf or txt
Download as pdf or txt
You are on page 1of 2

Contact Lens & Anterior Eye 36 (2013) 265–266

Contents lists available at ScienceDirect

Contact Lens & Anterior Eye


journal homepage: www.elsevier.com/locate/clae

Case report

Successful treatment of phlyctenular keratoconjunctivitis with topical


cyclosporin A
Olugbemisola Oworu, Pouya Alaghband ∗ , Colin Hutchinson
Huddersfield Royal Infirmary, UK

a r t i c l e i n f o

Article history:
Received 21 October 2012
Received in revised form 16 February 2013
Accepted 21 February 2013

Dear Sir,

We report a case of an 18 year-old female of Asian origin who


presented with phlyctenular keratoconjunctivitis (PKC) in the left
eye. This was resistant to conventional treatment but responded
satisfactorily to topical cyclosporin A 0.2% (CSA).

1. Case report

An 18-year-old Asian female presented with a 4 year history


of recurrent discomfort, redness and photophobia in the left eye.
There was no preceding trauma and she had no significant past
medical history. There was no clinical or radiological evidence of
tuberculosis, sarcoidosis, Behçet’s disease and Rosacea. She has pre-
viously been successfully treated for PKC in both eyes with steroid
eye drops.
She has bilateral posterior blepharitis and a limbal PKC in the left
eye (Fig. 1). There was no corneal infiltrates, inflamed pingueculum,
marginal corneal ulcer nor signs of herpetic keratitis. Visual acuity
was 6/6 bilaterally. The corneal sensation was intact. No palpable Fig. 1. Conjunctival phlycten, a small pinkish elevated nodule situated in the midst
preauricular node. On upper tarsus eversion examination she had of a hyperemic area at three o’clock position on the limbus. A leash of blood vessels
mild papillary reaction. can be seen running from the phlycten in a triangular fashion.
Initial treatment with lid hygiene, topical non-steroidal anti-
inflammatory drugs showed no marked improvement. Treatment months after treatment was initiated and there was no recurrence
with topical prednisolone acetate 1% four times daily with oral 2 year later (Fig. 2).
erythromycin 250 mg bd for 4 months showed no effect either. The
phlyctenular conjunctivitis endured in spite of this treatment. 2. Discussion
She was then commenced on CSA ointment 0.2%
(OPTIMMUNE® ) in the left eye and this led to a dramatic improve- Phlyctenular keratoconjunctivitis is a nodular inflammation of
ment within 2 weeks. The limbal phlycten completely resolved 2 the perilimbal tissues that occurs secondary to an allergic hyper-
sensitivity response of the cornea [1].
It is presumed to be type IV cell-mediated hypersensitiv-
∗ Corresponding author at: Huddersfield Royal Infirmary, Lindley, Huddersfield ity to staphylococcal antigens and mycobacterium tuberculosis
HD3 3EA, UK. Tel.: +44 1484347316. [2]. Other associations include worms [3] and parasites [4]. In a
E-mail address: [email protected] (P. Alaghband). case series from Korea, they found Staphylococcus epidermidis and

1367-0484/$ – see front matter © 2013 British Contact Lens Association. Published by Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.clae.2013.02.008
266 O. Oworu et al. / Contact Lens & Anterior Eye 36 (2013) 265–266

corneal infiltrate and neovascularisation. In few cases, the condition


can become refractory to steroids [7].
Topical CSA has been used in the treatment of severe
steroid-dependent childhood PKC [8]. CSA inhibits calcineurin, sub-
sequently down regulates IL-2 and T cell proliferation. This process
reduces inflammation. In a case series of 11 children by Doan et al.
the ocular tolerability of topical CSA 2% was excellent, blood levels
remained consistently below the detectable limits. Despite the the-
oretical increase in infection, they observed no local adverse events
[8].
This single case supports other studies (with more patients),
both in treatment efficacy and safety, that CsA is effective and safe
and may be an adjunct to more conservative or traditional treat-
ments in refractory cases of PKC.
No financial disclosure for authors to declare.

References

[1] Cullom RD, Chang B. Cornea: phylectenulosis. In: Cullom RD, Chang B, editors.
The Wills eye manual: office and emergency room diagnosis and treatment of
eye disease. Philadelphia, PA: J.B. Lippincott Co; 1994. p. 64–5.
Fig. 2. Complete resolution of the limbal phlycten.
[2] Abu el Asrar AM, Geboes K, Maudgal PC, et al. Immunocytological study of
phlyctenular eye disease. Int Ophthalmol 1987;10:33–9.
corynebacterium species in the meibum of patients with PKC. They [3] Jeffrey MP. Ocular diseases caused by nematodes. Am J Ophthalmol
1995;40:41–52.
also noted that phlyctens were mostly located in the inferior quad- [4] Hussein AA, Nasr ME. The role of parasitic infections in the etiology of phlyctenu-
rant of the cornea [5]. This observation supports the notion that lar eye disease. J Egypt Soc Parasitol 1991;21:865–8.
this is an immune response to lid based antigens which would sup- [5] Jo DH, Kim MK, Wee WR, Lee HJ. Analysis of clinical characteristics of
phlyctenular keratoconjunctivitis at a tertiary centre. J Korean Ophthalmol Soc
port the concept of an immune modulator as a logical adjunctive 2011;52(1):7–13.
treatment. [6] Zaidman GW, Brown SI. Orally administered tetracycline for phlyctenular kera-
The exact mechanism by which phlyctenule is produced is toconjunctivitis. Am J Ophthalmol 1981;92:173–82.
[7] Wagoner MD, Bajart AM, Allansmith MR. Phlyctenulosis. In: Fraunfelder FT, Roy
uncertain. Histologically, PKC consists of lymphocytes, histocytes FH, editors. Current ocular therapy, 3. Philadelphia, PA: W.B. Saunders Co; 1990.
and plasma cells. The treatment of mild to moderate cases is with p. 454–6.
eyelid hygiene and oral antibiotics especially in the presence of [8] Doan S, Gabison E, Gatinel D, Duong MH, Abitol O, et al. Topical cyclosporine A
in severe steroid-dependent childhood phlyctenular keratoconjunctivitis. Am J
staphylococcal or rosacea related blepharitis [6]. Topical cortico- Ophthalmol 2006;141(Jan (1)):62–6.
steroid is the mainstay treatment option for severe disease with

You might also like